ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Artiva Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$5.89+0.04 (+0.68%)
Close on Oct 19, 2026
- Market cap
- $232.14M
- P/E (TTM)
- –
- Dividend yield
- –
Artiva Biotherapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Artiva Biotherapeutics | Industry median |
|---|---|---|
| Market Cap | $287.96M | $197.05M |
| Enterprise Value | -$61.44M | $106.56M |
| PB Ratio | 0.83 | 2.14 |
| P/TBV Ratio | 0.83 | 2.46 |
Income (trailing twelve months)
| Measure | Artiva Biotherapeutics | Industry median |
|---|---|---|
| Operating Income | -$96.15M | -$21.44M |
| Net Income | -$90.82M | -$22.46M |
| EBITDA | -$93.46M | -$16.91M |
| EPS (Diluted) | -$3.31 | -$0.83 |
Returns
| Measure | Artiva Biotherapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -36.6% | -53.1% |
| Return on Assets (ROA) | -33.8% | -41.0% |
| Return on Invested Capital (ROIC) | -3202.9% | -32.0% |
| Return on Capital Employed (ROCE) | -27.2% | -37.8% |
Balance sheet
| Measure | Artiva Biotherapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $349.40M | $62.42M |
| Net Cash (Debt) | $349.40M | $15.68M |
| Net Cash Per Share | $7.15 | $0.65 |
| Equity (Book Value) | $347.50M | $48.79M |
| Book Value Per Share | $7.11 | $1.36 |
| Tangible Book Value | $347.50M | $23.06M |
| Working Capital | $337.70M | $75.77M |
Financial position
| Measure | Artiva Biotherapeutics | Industry median |
|---|---|---|
| Current Ratio | 24.16 | 3.30 |
| Quick Ratio | 23.96 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Artiva Biotherapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$75.23M | -$12.35M |
| Capital Expenditures | -$1.68M | -$1.06M |
| Free Cash Flow | -$76.91M | -$20.28M |
| FCF Per Share | -$1.57 | -$0.41 |
Efficiency
| Measure | Artiva Biotherapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$873.28K | -$732.08K |
| Employee Count | 104 | 73 |
Dividends and yields
| Measure | Artiva Biotherapeutics | Industry median |
|---|---|---|
| Earnings Yield | -31.5% | -21.2% |
| FCF Yield | -26.7% | -7.64% |
Shares
| Measure | Artiva Biotherapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 48,890,100 | 59,128,900 |
| Float | 15,331,400 | 48,744,500 |
| Shares Held by Insiders | 68.6% | 11.8% |
| Shares Held by Institutions | 83.2% | 59.4% |
Scores
| Measure | Artiva Biotherapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 6.98 | 0.10 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Artiva Biotherapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.